CL2019003154A1 - Proceso de preparación de un compuesto intermediario de fórmula (vi) para la preparación de compuestos de cannabidiol. (divisional solicitud 201800079) - Google Patents

Proceso de preparación de un compuesto intermediario de fórmula (vi) para la preparación de compuestos de cannabidiol. (divisional solicitud 201800079)

Info

Publication number
CL2019003154A1
CL2019003154A1 CL2019003154A CL2019003154A CL2019003154A1 CL 2019003154 A1 CL2019003154 A1 CL 2019003154A1 CL 2019003154 A CL2019003154 A CL 2019003154A CL 2019003154 A CL2019003154 A CL 2019003154A CL 2019003154 A1 CL2019003154 A1 CL 2019003154A1
Authority
CL
Chile
Prior art keywords
preparation
formula
intermediate compound
preparation process
cannabidiol compounds
Prior art date
Application number
CL2019003154A
Other languages
English (en)
Inventor
Lukas Dialer
Denis Petrovic
Ulrich Weigl
Original Assignee
Noramco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57730761&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019003154(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Noramco Inc filed Critical Noramco Inc
Publication of CL2019003154A1 publication Critical patent/CL2019003154A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/11—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/11—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms
    • C07C37/14—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms by addition reactions, i.e. reactions involving at least one carbon-to-carbon unsaturated bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

PROCESO DE PREPARACIÓN DE UN COMPUESTO INTERMEDIARIO DE FÓRMULA (VI) PARA LA PREPARACIÓN DE COMPUESTOS DE CANNABIDIOL O UN DERIVADO DEL MISMO.
CL2019003154A 2015-07-10 2019-11-04 Proceso de preparación de un compuesto intermediario de fórmula (vi) para la preparación de compuestos de cannabidiol. (divisional solicitud 201800079) CL2019003154A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562191097P 2015-07-10 2015-07-10
US15/199,528 US10059683B2 (en) 2015-07-10 2016-06-30 Process for the production of cannabidiol and delta-9-tetrahydrocannabinol

Publications (1)

Publication Number Publication Date
CL2019003154A1 true CL2019003154A1 (es) 2020-03-06

Family

ID=57730761

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2018000079A CL2018000079A1 (es) 2015-07-10 2018-01-10 Proceso para la produccion de cannabidiol y delta-9-tetrahidrocannabinol.
CL2019003154A CL2019003154A1 (es) 2015-07-10 2019-11-04 Proceso de preparación de un compuesto intermediario de fórmula (vi) para la preparación de compuestos de cannabidiol. (divisional solicitud 201800079)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2018000079A CL2018000079A1 (es) 2015-07-10 2018-01-10 Proceso para la produccion de cannabidiol y delta-9-tetrahidrocannabinol.

Country Status (21)

Country Link
US (4) US20170008869A1 (es)
EP (2) EP3319952B8 (es)
JP (2) JP6810842B2 (es)
CN (1) CN108137526A (es)
AU (2) AU2016294264B2 (es)
BR (1) BR112018000497A2 (es)
CA (1) CA2992043C (es)
CL (2) CL2018000079A1 (es)
CO (1) CO2018001290A2 (es)
CR (1) CR20180094A (es)
DK (1) DK3319952T3 (es)
EC (1) ECSP18010065A (es)
ES (2) ES3010714T3 (es)
HK (1) HK1255390A1 (es)
IL (1) IL256750A (es)
MX (1) MX2018000354A (es)
MY (1) MY182971A (es)
NZ (1) NZ738925A (es)
PH (1) PH12018500093A1 (es)
PT (1) PT3319952T (es)
WO (1) WO2017011210A1 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US20170008869A1 (en) * 2015-07-10 2017-01-12 Noramco, Inc. Process for the production of cannabidiol and delta-9-tetrahydrocannabinol
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
US10640482B2 (en) 2017-07-21 2020-05-05 University Of South Florida Synthesis of cannabinoids
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
CA3091088A1 (en) * 2018-02-13 2019-08-22 Beetlebung Pharma Ltd. Cannabinoid derivatives and conjugates and uses thereof
KR102374793B1 (ko) * 2018-02-20 2022-03-17 엠와이엠디 파마슈티컬스 (플로리다), 인코포레이티드 물질 중독 및 다른 장애 치료용 유전자 변형 칸나비스 사티바 식물 및 변형된 칸나비노이드 화합물
EP4620940A3 (en) 2018-06-28 2025-12-17 Symrise AG Synthesis of (+)-cannabinoids and their therapeutic effects
US10736869B2 (en) 2018-07-16 2020-08-11 ECS Health Sciences, Inc. Compositions and methods related to cannabinoids, terpenoids and essential oils
CN108863768A (zh) * 2018-08-03 2018-11-23 上海华堇生物技术有限责任公司 3,5-二甲氧基苯甲酰氯的制备方法
EP3840854A4 (en) 2018-08-20 2022-06-29 Bessor Pharma, LLC Novel cannabinoids and cannabinoid acids and their derivatives
US12144795B2 (en) * 2018-09-05 2024-11-19 Purisys Llc Cannabidiol compositions having modified cannabinoid profiles
EP3864000A4 (en) 2018-10-10 2022-08-10 Treehouse Biosciences, Inc. CANNABIGEROL SYNTHESIS
EP3653596A1 (en) * 2018-11-14 2020-05-20 Indena S.p.A. Continuous flow synthesis of cannabidiol
DE102019104563A1 (de) 2019-02-22 2020-08-27 Chiracon Gmbh Verfahren zur Herstellung von Cannabidiol
CN109970516A (zh) * 2019-03-20 2019-07-05 栾云鹏 一种工业化制备高纯度高收率的大麻酚类物质的合成方法
WO2020214574A1 (en) 2019-04-15 2020-10-22 Trustees Of Boston University One-step flow-mediated synthesis of cannabidiol (cbd) and derivatives
CN111943813B (zh) 2019-05-17 2023-04-14 上海特化医药科技有限公司 大麻二酚类化合物的制备方法
EP3959193A4 (en) * 2019-05-23 2022-07-13 Kare Chemical Technologies Inc. Catalytic cannabinoid processes and precursors
US20230183157A1 (en) * 2019-05-31 2023-06-15 Purisys Llc Processes for the preparation of halogenated dihydroxybenzene compounds
ES3037766T3 (en) 2019-06-11 2025-10-07 Symrise Ag Synthesis and purification of cannabigerol and its application
WO2020248058A1 (en) 2019-06-11 2020-12-17 Canopy Growth Corporation Improved methods for converting cannabidiol into delta 8-tetrahydrocannabinol
WO2020252277A1 (en) * 2019-06-13 2020-12-17 Isomerz, Inc. Making delta 8 thc, delta 10 thc and/or cannabinol from cbd
WO2020252369A1 (en) * 2019-06-14 2020-12-17 Purisys Llc Crystalline cannabigerol
GB201910389D0 (en) * 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
CA3150642A1 (en) 2019-09-09 2021-03-18 Kamaluddin Abdur-Rashid CANNABINOID DERIVATIVES, PRECURSORS AND USES
US11542243B1 (en) 2019-09-26 2023-01-03 FusionFarms, LLC Method of converting delta9-THC to delta10-THC and the purification of the delta10-THC by crystallization
EP4069215B1 (en) 2019-12-06 2026-07-01 Jlabs Beauty LLC Topical compositions containing rose oil and cannabidiol, and processes for their preparation and use
CN115066238A (zh) * 2019-12-27 2022-09-16 海湾医学公司 大麻色原烯和相关大麻素的制备
CN113087743B (zh) * 2020-01-08 2023-04-28 成都百裕制药股份有限公司 四氢大麻酚衍生物及其制备方法和在医药上的应用
US12545694B2 (en) 2020-01-08 2026-02-10 Chengdu Baiyu Pharmaceutical Co., Ltd. Cannabidiol derivatives, preparation method thereof and use thereof
WO2021150885A1 (en) * 2020-01-24 2021-07-29 Perkinelmer Health Sciences, Inc. Cannabinoid derivatives
US10981849B1 (en) * 2020-02-20 2021-04-20 Sci Pharmtech Inc. Method for preparing cannabinoids
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
AU2021235467B2 (en) * 2020-03-12 2026-04-02 Council Of Scientific And Industrial Research Process for the synthesis of cannabidiol and intermediates thereof
CN116194431B (zh) * 2020-03-31 2026-01-02 植物疗法有限公司 萜酚化合物及其用途
EP4153306A4 (en) 2020-05-22 2024-06-26 Ilera Derm LLC Compositions for treating acne and dermatological conditions
GB202009321D0 (en) 2020-06-18 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
CN112094257B (zh) * 2020-08-19 2023-08-22 公安部禁毒情报技术中心 一种△-9四氢大麻酚的制备方法
CN112811980B (zh) * 2020-12-01 2022-03-25 山东金城金奥医药科技有限公司 一种绿色光氧化连续制备大麻二酚中间体的方法
AU2021400338A1 (en) 2020-12-17 2023-07-13 Nalu Bio, Inc. Synthesis of cannabidiol and analogs thereof, and related compounds, formulations, and methods of use
JP7858686B2 (ja) 2020-12-21 2026-05-14 アイソセレス ファーマシューティカルズ，インコーポレイテッド 非経口カンナビノイド配合物およびその使用
US11242330B1 (en) * 2021-02-25 2022-02-08 Acid Neutral Alkaline Laboratory Organic catalyst and method for preparation of aromatic tricyclic pyrans
US11242328B1 (en) * 2021-02-25 2022-02-08 Acid Neutral Alkaline Laboratory Heterogeneous catalyst and method for preparation of aromatic tricyclic pyrans
US20220306598A1 (en) * 2021-03-25 2022-09-29 Precision Extraction Corporation Method for highly selective conversion of cbd to delta-8 thc
US11352337B1 (en) * 2021-06-02 2022-06-07 Acid Neutral Alkaline Laboratory Zeolite catalyst and method for preparation of aromatic tricyclic pyrans
CN113603568A (zh) * 2021-07-19 2021-11-05 厦门朝阳生物工程有限公司 一种大麻二酚的制备方法
WO2023086447A2 (en) * 2021-11-12 2023-05-19 Pureform Global, Inc. A method for the synthesis of cannabinol
EP4436559A4 (en) 2021-11-27 2025-04-02 Miralogx LLC SYNTHETIC CANNABINOID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT
EP4565573B1 (en) 2022-08-05 2026-04-15 Salud & Semillas, S.L. Cannabinoid synthesis starting out from olivetol and terpene in dichloromethane with fecl3 * 6h2o as catalyst
JP2025527136A (ja) 2022-08-11 2025-08-20 カーディオル セラピューティクス インコーポレイテッド 安定した注射カンナビジオール製剤
CN117700304B (zh) * 2022-09-01 2026-07-28 卡那比生物科学有限公司 一种大麻二酚的制备方法及其应用
GB2642523A (en) * 2024-07-12 2026-01-14 Sonas Pharmaceuticals N I Ltd Novel halogenated cannabinoid derivatives
GB202417688D0 (en) 2024-12-02 2025-01-15 Celadon Pharmaceuticals Plc Novel process

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH473075A (de) 1966-11-04 1969-05-31 Theodor Dr Petrzilka Verfahren zur Herstellung von in 2-Stellung substituierten Resorcinderivaten
DE4100441A1 (de) 1991-01-09 1992-07-16 Mack Chem Pharm Verfahren zur herstellung von 6,12-dihydro-6-hydroxy-cannabidiol und dessen verwendung zur herstellung von trans-delta-9-tetrahydrocannabinol
AU6088200A (en) 1999-07-12 2001-01-30 Virginia Commonwealth University Novel vasodilator cannabinoid analogs
EP1482917B1 (en) * 2002-02-01 2019-05-08 GW Pharma Limited Compositions comprising cannabidiolic acid for treatment of nausea, vomiting, emesis, motion sickness or like conditions
GB2393182B (en) * 2002-09-23 2007-03-14 Gw Pharma Ltd Method of preparing cannabidiol from plant material
US7169942B2 (en) * 2003-05-20 2007-01-30 University Of Tennessee Research Foundation Cannabinoid derivatives, methods of making, and use thereof
US7323576B2 (en) 2004-10-01 2008-01-29 Alphora Research Inc. Synthetic route to dronabinol
TWI369203B (en) * 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
DE102005028937B4 (de) * 2005-06-22 2009-07-23 Bionorica Ag Verfahren zur Herstellung von Dronabinol
EP2578561A1 (en) * 2005-09-29 2013-04-10 Albany Molecular Research, Inc. Processes for the production of cannabidiol derivatives and intermediates thereof
CA2751741C (en) * 2008-02-06 2018-07-10 Mallinckrodt Inc. Process for the preparation of (-) -delta 9-tetrahydrocannabinol
DE102009019322A1 (de) * 2009-04-30 2010-11-11 The Health Concept Gmbh Verfahren zur Herstellung von Synthetischen Cannabinoiden
WO2016153347A1 (en) * 2015-03-23 2016-09-29 Echo Pharmaceuticals B.V. Cannabidiol isolate from industrial-hemp and use thereof in pharmaceutical and/or cosmetic preparations
DK3302437T4 (da) * 2015-05-28 2026-02-23 Fresh Cut Dev Llc Stabile cannabinoidformuleringer
US20170008869A1 (en) * 2015-07-10 2017-01-12 Noramco, Inc. Process for the production of cannabidiol and delta-9-tetrahydrocannabinol

Also Published As

Publication number Publication date
MY182971A (en) 2021-02-05
AU2016294264B2 (en) 2019-06-13
JP2018522944A (ja) 2018-08-16
ES2784881T3 (es) 2020-10-01
DK3319952T3 (da) 2020-03-23
US20210061781A1 (en) 2021-03-04
ES3010714T3 (en) 2025-04-04
IL256750A (en) 2018-03-29
US10059683B2 (en) 2018-08-28
HK1255390A1 (zh) 2019-08-16
CA2992043C (en) 2020-04-14
PH12018500093A1 (en) 2018-07-09
WO2017011210A1 (en) 2017-01-19
CO2018001290A2 (es) 2018-04-19
EP3319952B8 (en) 2020-03-11
US20170008868A1 (en) 2017-01-12
PT3319952T (pt) 2020-04-22
EP3722276C0 (en) 2025-01-08
CR20180094A (es) 2018-06-14
EP3319952B1 (en) 2020-02-05
JP2020037596A (ja) 2020-03-12
EP3722276A1 (en) 2020-10-14
EP3722276B1 (en) 2025-01-08
US20170008869A1 (en) 2017-01-12
JP6810842B2 (ja) 2021-01-13
CA2992043A1 (en) 2017-01-19
BR112018000497A2 (pt) 2018-09-11
AU2019229416A1 (en) 2019-10-03
AU2016294264A1 (en) 2018-02-01
CN108137526A (zh) 2018-06-08
CL2018000079A1 (es) 2018-08-24
US10844035B2 (en) 2020-11-24
US20180319763A1 (en) 2018-11-08
EP3319952A1 (en) 2018-05-16
ECSP18010065A (es) 2018-05-31
MX2018000354A (es) 2018-08-15
NZ738925A (en) 2019-05-31

Similar Documents

Publication Publication Date Title
AR132627A2 (es) Procesos para preparar compuestos intermediarios de utilidad para sintetizar compuestos de carbamoilpiridona policíclicos
CL2020001852A1 (es) Procesos de preparación de s-ketamina o clorhidrato de s-ketamina o productos derivados de éste. (divisional solicitud 201901066)
ECSP20075270A (es) Compuestos
SG11201806348PA (en) Steroid derivative fxr agonist
MX379920B (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
BR112017009648A2 (pt) composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto.
CU20170015A7 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
UY36244A (es) Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen
BR112016028476A8 (pt) compostos, composição, uso de um composto e método para o combate dos fungos nocivos
MX2020014097A (es) Lipidos novedosos.
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
MX2020006799A (es) Derivados de oxi-fluoropiperidina como inhibidor de cinasa.
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
MX375638B (es) Proceso para la fabricación de medicamentos.
MX380550B (es) Sintesis de indazoles.
SG10201805896SA (en) PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS
EA201991241A1 (ru) Способ получения метоксиметилпиридин дикарбоксилата
CL2020000376A1 (es) Compuesto pentacíclico.
CL2018002756A1 (es) Un proceso mejorado para la preparación de tartrato de butorfanol.
MX2017015662A (es) Procesos para la preparacion de derivados acidos de n-acetilgalactosamina (galnac).
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
BR112018070345A2 (pt) processo para a preparação de derivados de 4-aminoindano e amidas de aminoindano relacionadas
MX381489B (es) Compuesto biciclico y uso del mismo para la inhibicion de suv39h2.